On July 31, 2025, Mankind Pharma's Board approved the acquisition of the Women Health Rx Portfolio from Bharat Serums and Vaccines at an undisclosed lump sum amount, alongside approving an interim dividend of ₹1 per share and raising up to ₹1,000 Crores through unsecured funding instruments.